Jacobson Resonance Enterprises Inc. Applies For European CE-Mark Approval
BOCA RATON, Fla., Nov. 19 /PRNewswire/ -- With the assistance of board member Alfonso Serrato, Jacobson Resonance Enterprises Inc. (OTC Bulletin Board: JRSE) announced today that it has applied for a Certificate of Conformance (commonly known as a CE-Mark) which is equivalent to seeking FDA marketing approval in the U.S. This will allow the Company to manufacture and distribute its proprietary bio-electromagnetic medical equipment in the European Common Market for the treatment and amelioration of pain.
"The approval will give the Company access to a potential market of approximately 400 million people," said Dr. Jerry Jacobson, president of Jacobson Resonance Enterprises and inventor of the technology. The Company estimates that the CE-Mark will be granted by the governmental authorities in the second quarter of 1999.
Following a successful symposium held in Marbella, Spain on August 21, 1998, construction began on a training and educational facility center to serve as the Corporation's European headquarters and to coordinate/respond to multiple commercial interests and applications. The grand opening is set for the end of March 1999.
"We're currently completing double-blind randomized clinical trials on pain pursuant to FDA approval in the United States," added Jacobson.
Jacobson Resonance Enterprises, Inc. is a leader in the emerging field of bio-electromagnetic resonance. The Company's proprietary technology known as Jacobson Resonance has applications that cut across the medical, pharmaceutical, food and beverage, construction, and environmental industries.
Forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission.
SOURCE Jacobson Resonance Enterprises Inc.
|
